These drugs (casirivimab and imdevimab) are antibodies like the ones produced by our bodies when they are faced with the COVID-19 virus. They act by blocking the ability of the virus to infect our bodyâ€™s cells.Casirivimab and imdevimab are a combination of two recombinant human antibodies that targets a different part of the spike protein, the part of the coronavirus responsible for infecting human cells.  
